Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study

Abstract Background Intravenous immunoglobulin (IVIG) has been used as an immunomodulatory therapy to counteract severe systemic inflammation in coronavirus disease 2019 (COVID-19). But its use in COVID-19 related acute respiratory distress syndrome (ARDS) is not well established. Methods We conduct...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Husain S. Ali, Moustafa S. Elshafei, Mohamed O. Saad, Hassan A. Mitwally, Mohammad Al Wraidat, Asra Aroos, Nissar Shaikh, Dore C. Ananthegowda, Mohamed A. Abdelaty, Saibu George, Abdulqadir J. Nashwan, Ahmed S. Mohamed, Mohamad Y. Khatib
Format:	article
Langue:	EN
Publié:	BMC 2021
Sujets:	Acute respiratory distress syndrome COVID-19 ICU mortality Intravenous immunoglobulin Mechanical ventilation Diseases of the respiratory system RC705-779
Accès en ligne:	https://doaj.org/article/386dc40f31d34a41ab3d998b93a9a9e6
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study

Documents similaires